2026-06-25: DEUSG Virtual

 Summary

Strength Rounding Requirements Update

SI Team provided an update on strength rounding requirements, presenting a draft matrix that maps various requirements to proposed solutions including scientific approaches from Canada and Australia, multiple axioms, and reduced fraction representation. He requested team members to contribute their requirements to the forum discussion to help create a more comprehensive briefing note.

Hydrated Substances System Implementation

The group discussed implementing hydrated substances and PAI in the system, with members explaining that while the solution approach is sound, it requires testing feedback from extensions where it is used like CA, before moving forward. Members outlined proposal to promote attributes from Canada extension to enable better classification of clinical drugs, noting this would address technical debt and content issues. SI team emphasized the need for further discussion about whether the Canadian new attributes should be a subtype, modification, or sibling, and highlighted the potential to deliver this through batch promotion of substance modeling for hydration.

Form Modeling and Attribute Updates

The team discussed ongoing work on modeling forms after transformation, with plans to test new attributes in the International Edition before promoting changes to production. They debated whether to introduce new attributes for administrative DOS forms, with members arguing for more precision in modeling the actual administered form rather than the manufacturer's form. The group also reviewed the approach for products with no active ingredients, confirming a previously agreed solution and noting the need to update editorial guidance to help extensions follow the same approach.

MRCM Implementation Guidance Discussion

SI Team and members discussed the need for editorial guidance on implementing MRCM changes, particularly regarding how to document different implementation scenarios and usage cases. Members shared insights from research across different countries, noting that Argentina is most aligned with international release followed by Canada, Norway, and Ireland, with Ireland using less granular clinical drugs and different approaches to presentation strength versus concentration strength. The team identified challenges with content coordination across countries releasing simultaneously and discussed the need for better collaboration and versioning mechanisms to avoid duplication and improve interoperability.

Drug Classification Hierarchy Review

UK raised a question about the naming of the substance hierarchy for non-steroidal anti-inflammatory drugs, particularly regarding sulfasalazine's classification, and proposed submitting a CRS request for further review. SI team agreed to investigate the issue in depth.

Canadas first publication of their Drug Extension was noted and major accomplishment for Canada, and all team members involved congratulated.

Alejandro announced that the group would take a break during the summer months with no live meetings scheduled for July and August, and planned to reconvene in September with the hope of publishing a new implementation guide for the drug model.